BLASOLUTIONINJECTION
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IRA Negotiated
MERILOG (insulin aspart-szjj) by Sanofi is insulin, including insulin aspart products is the regulation of glucose metabolism. First approved in 2025.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MERILOG (insulin aspart-szjj) is a rapid-acting insulin analog approved by the FDA on February 14, 2025, as a biosimilar to Novo Nordisk's NovoLog. It regulates glucose metabolism by stimulating peripheral glucose uptake in muscle and fat while inhibiting hepatic glucose production, making it suitable for diabetes management.
Growth
Early-stage biosimilar in growth phase with significant pricing pressure; commercial teams will focus on market penetration and payer access strategies.
Mechanism of Action
insulin, including insulin aspart products is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis,…
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MERILOG offers exposure to biosimilar commercialization, payer negotiations, and launch-phase rapid growth—a high-energy environment with emphasis on market access over traditional detailing. Career trajectory hinges on rapid adoption metrics and competitive differentiation in a commoditizing insulin market.
Brand Manager
Worked on MERILOG at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.